Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2016 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. Look for statements about deal size, customer size, scope, etc., compared to past. In the transcript, Yaki says: "Our [SIEM] solution increased globally and our efforts to reach customer is more than 1,000 employees who can make larger commitments for us over the time are showing results." That suggests they are targeting larger customers, but does it say that the deals are now larger than before? He says "make larger commitments" - that could be about customer size, not necessarily deal size escalation. But he says "over the time are showing results" - implies that they are now getting larger commitments from customers with more than 1,000 employees. However, is that a comparison to their own past? Possibly, but it's vague. Later: "We continue to have access globally and a cost medium and large enterprises but our focus on engagement with companies with 1,000 employees or more is key driver for our growth." That's about focus, not necessarily that deals are larger. Gili says: "We've successful broadened our relationship with existing customers and also increased new customer additions." That's about volume. No explicit statement about average deal size increasing. They mention one deal >$1 million with a new customer, but that's not framed as part of an upward drift. Yaki: "We see less and less competition overall from and on DatAlert almost none." Not about size. Yaki: "We are everyday benefiting from increased awareness and increased demand particularly when the emergency spending happen we didn’t benefit from it so much, but we are benefiting from a very thoughtful approach to our security." Not about size. Yaki: "We see significantly a more budget coming toward a solution like ours." That's about budget, not deal size. Yaki: "It’s not, its enterprise sale, it's still need to do the regular sales cycle just becoming much more just predictable customers are coming to us." That suggests sales cycle is more predictable, not larger deals. Yaki: "There is a lot of attention from sea level and they're definitely selling move to C Sales with more involvement of the business." That's about who they sell to, not size.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.